Ozanezumab Biosimilar - Research Grade

Human

NOGO-A

>1mg/ml

Human IgG1 (L235A/G237A/E356D/M358L)-Kappa

Atinumab Biosimilar - Research Grade (ICH5361)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NQC3

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ozanezumab, an anti-Nogo-A (RTN4) antibody, supplied strictly for research use only. It is built around the same target and human IgG1-kappa framework concept as the originator biologic but is manufactured as a research reagent, not the clinical drug, and is not intended for human or veterinary use. The molecule is engineered with Fc-attenuating mutations, consistent with the originator's effector-reduced design, making it useful when researchers want target engagement without strong Fc-mediated effector function. Typical applications include use as a well-characterized positive or benchmarking control in binding and neutralization assays, as a tool for probing Nogo-A biology in vitro, in ADC or antibody-engineering workflows, and in preclinical model development. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and can be supplied in bulk milligram-to-gram quantities and as an in-vivo-standard grade to support scaled preclinical and assay-development programs. No clone identity is implied; the analog is defined by its target specificity and sequence framework. Nogo-A is the largest isoform of Reticulon 4 (RTN4; UniProt Q9NQC3), a CNS-enriched membrane protein and one of the principal myelin-associated inhibitors of axonal growth and regeneration. Two functional regions drive its inhibitory activity: the amino-terminal Nogo-A-specific domain (including the Nogo-A-Delta20 region) and the Nogo-66 loop. Nogo-66 signals through Nogo receptor 1 (NgR1) with co-receptors such as p75/TROY and LINGO-1, while Nogo-A-Delta20 acts via sphingosine-1-phosphate receptor 2 (S1PR2). Engagement of these pathways activates RhoA/ROCK signaling, causing growth-cone collapse and restricting neurite outgrowth, plasticity, and circuit remodeling. Through these mechanisms Nogo-A contributes to the limited regenerative capacity of the adult mammalian CNS. It is studied extensively in spinal cord injury, stroke, and motor neuron disease, where elevated Nogo-A has been reported. RTN4 isoforms also localize to the endoplasmic reticulum and help shape ER membrane morphology.

RTN4, reticulon 4, Neurite Outgrowth Inhibitor

Detects human RTN4

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

LAGA

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.